Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Processa PharmaceuticalsPCSA | Open-market buy | 06/15 | 06/16 | 2,654 sh | $2.22 | $5,891.88 | +24.7% | |
David YoungPres. Research & Development | Processa PharmaceuticalsPCSA | Open-market buy | 06/15 | 06/16 | 2,067 sh | $2.22 | $4,588.74 | +12.1% |
George K. NgCEO | Processa PharmaceuticalsPCSA | Open-market buy | 06/15 | 06/16 | 2,465 sh | $2.22 | $5,472.3 | +24.7% |
Wendy GuyChief Administrative Officer | Processa PharmaceuticalsPCSA | Open-market buy | 06/15 | 06/16 | 2,118 sh | $2.22 | $4,701.96 | +21.5% |
Patrick LinChief Business - Strategy Off | Processa PharmaceuticalsPCSA | Open-market buy | 06/15 | 06/16 | 1,831 sh | $2.22 | $4,064.82 | +20.0% |
Processa PharmaceuticalsPCSA | Open-market buy | 05/29 | 06/01 | 2,292 sh | $2.57 | $5,890.44 | +27.1% | |
David YoungPres. Research & Development | Processa PharmaceuticalsPCSA | Open-market buy | 05/29 | 06/01 | 1,786 sh | $2.57 | $4,590.02 | +11.6% |
George K. NgCEO | Processa PharmaceuticalsPCSA | Open-market buy | 05/29 | 06/01 | 2,129 sh | $2.57 | $5,471.53 | +27.2% |
Wendy GuyChief Administrative Officer | Processa PharmaceuticalsPCSA | Open-market buy | 05/29 | 06/01 | 1,829 sh | $2.57 | $4,700.53 | +22.8% |
Patrick LinChief Business - Strategy Off | Processa PharmaceuticalsPCSA | Open-market buy | 05/29 | 06/01 | 1,582 sh | $2.57 | $4,065.74 | +20.8% |
Processa PharmaceuticalsPCSA | Open-market buy | 05/15 | 05/19 | 1,984 sh | $2.97 | $5,892.48 | +30.6% | |
David YoungPres. Research & Development | Processa PharmaceuticalsPCSA | Open-market buy | 05/15 | 05/19 | 1,545 sh | $2.97 | $4,588.65 | +11.2% |
Processa PharmaceuticalsPCSA | Open-market buyAmendment | 04/15–05/15 | 05/19 | 3,686 sh2 trades | $2.97avg. | $10,947.42 | +88.7% | |
Wendy GuyChief Administrative Officer | Processa PharmaceuticalsPCSA | Open-market buy | 05/15 | 05/19 | 1,583 sh | $2.97 | $4,701.51 | +24.6% |
Patrick LinChief Business - Strategy Off | Processa PharmaceuticalsPCSA | Open-market buy | 05/15 | 05/19 | 1,369 sh | $2.97 | $4,065.93 | +22.0% |
Sian BigoraChief Development Officer | Processa PharmaceuticalsPCSA | Open-market buyAmendment | 04/30 | 05/19 | 1,971 sh | $2.71 | $5,341.41 | +35.8% |
Processa PharmaceuticalsPCSA | Open-market buy | 04/30 | 05/01 | 2,190 sh | $2.69 | $5,891.1 | +50.8% | |
David YoungPres. Research & Development | Processa PharmaceuticalsPCSA | Open-market buy | 04/30 | 05/01 | 1,706 sh | $2.69 | $4,589.14 | +14.1% |
George K. NgCEO | Processa PharmaceuticalsPCSA | Open-market buy | 04/30 | 05/01 | 2,034 sh | $2.69 | $5,471.46 | +51.1% |
Wendy GuyChief Administrative Officer | Processa PharmaceuticalsPCSA | Open-market buy | 04/30 | 05/01 | 1,748 sh | $2.69 | $4,702.12 | +37.2% |